Clinical Trial Update: A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing eribulin to physician's choice in advanced non-small cell lung cancer has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)

Snippet

Sponsor: Eisai Inc. | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: COMPLETED | Results posted: 2017-03-01